Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025)

Amylyx Pharmaceuticals has reported Accumulated Depreciation for 5 years, with the latest figure at $1.6 million in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 14.35% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $1.6 million, a 14.35% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 14.35% from the prior year.
• Accumulated Depreciation was $1.6 million for Q4 2025 at Amylyx Pharmaceuticals, up from $1.4 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $1.6 million in Q4 2023, with the low at $53000.0 in Q4 2021.
• Average Accumulated Depreciation over 5 years is $1.0 million, with a median of $1.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Depreciation surged 918.87% in 2022, then retreated 16.52% in 2024.
• Over 5 years, Accumulated Depreciation stood at $53000.0 in 2021, then soared by 918.87% to $540000.0 in 2022, then soared by 201.48% to $1.6 million in 2023, then slipped by 16.52% to $1.4 million in 2024, then gained by 14.35% to $1.6 million in 2025.
• The last three Accumulated Depreciation figures came in at $1.6 million (Q4 2025), $1.4 million (Q4 2024), and $1.6 million (Q4 2023), per Business Quant data.